BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ure DR, Trepanier DJ, Mayo PR, Foster RT. Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH). Expert Opinion on Investigational Drugs 2020;29:163-78. [DOI: 10.1080/13543784.2020.1703948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD/NASH: Targets and therapy. Pharmacol Res 2021;167:105484. [PMID: 33771699 DOI: 10.1016/j.phrs.2021.105484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Naguib M, Abou Elfotouh M, Wifi MN. Elevated Serum Cyclophilin D Level is Associated with Nonalcoholic Fatty Liver Disease and Higher Fibrosis Scores in Patients with Diabetes Mellitus. Int J Gen Med 2021;14:4665-75. [PMID: 34434058 DOI: 10.2147/IJGM.S322986] [Reference Citation Analysis]
3 Haleckova A, Benek O, Zemanová L, Dolezal R, Musilek K. Small‐molecule inhibitors of cyclophilin D as potential therapeutics in mitochondria‐related diseases. Medicinal Research Reviews. [DOI: 10.1002/med.21892] [Reference Citation Analysis]
4 Li FX, Zhang QZ, Li SJ, Lin G, Huo XY, Lan Y, Yang Z. Semisynthesis of CRV431. Org Lett 2021;23:3421-5. [PMID: 33844557 DOI: 10.1021/acs.orglett.1c00881] [Reference Citation Analysis]